Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

Current Opinion in Pharmacology
Timothy A YapPaul Workman

Abstract

The strategy of 'drugging the cancer kinome' has led to the successful development and regulatory approval of several novel molecular targeted agents. The spotlight is now shifting to the phosphatidylinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway as a key potential target. This review details the role of the pathway in oncogenesis and the rationale for inhibiting its vital components. The focus will be on the progress made in the development of novel therapies for cancer treatment, with emphasis placed on agents that have entered clinical development. Strategies involving horizontal and vertical blockade of the pathway, as well as the use of biomarkers to select appropriate patients and to provide proof of target modulation will also be highlighted. Finally, we discuss the issues and limitations involved with targeting the PI3K-AKT-mTOR pathway, and predict what the future may hold for these novel anticancer therapeutics.

Citations

Sep 15, 2010·Annals of Hematology·Pinelopi ArgyriouDimitra Rontogianni
Dec 6, 2011·Pflügers Archiv : European journal of physiology·Mátyás CzepánPéter Hegyi
Aug 24, 2012·International Journal of Clinical Oncology·Tamotsu Sudo
Jul 10, 2010·Breast Cancer Research and Treatment·Mohammed A AleskandaranyAndrew R Green
Aug 7, 2012·Journal of Mammary Gland Biology and Neoplasia·Justin Cidado, Ben Ho Park
Sep 24, 2013·Molecular and Cellular Biochemistry·Guo-Bin WangWei-Fang Zhang
Aug 1, 2009·Nature Reviews. Drug Discovery·Pixu LiuJean J Zhao
Jul 25, 2009·Proceedings of the National Academy of Sciences of the United States of America·Deliang GuoPaul S Mischel
Dec 29, 2009·Assay and Drug Development Technologies·Jolanta VidugirieneSaid A Goueli
Nov 19, 2011·Toxicological Sciences : an Official Journal of the Society of Toxicology·Jonathan P RenningerDiane W Morel
Mar 29, 2012·Advances in Urology·Marco A De Velasco, Hirotsugu Uemura
Feb 25, 2010·Cancer Research·Paul WorkmanRob L M van Montfort
Dec 21, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Saadia A AzizHarriet M Kluger
Jan 18, 2011·Hematology·Thomas E Witzig, Mamta Gupta
Nov 21, 2012·Journal of Translational Medicine·Bing ChenShufang Liang
Aug 1, 2009·Journal of Hematology & Oncology·Jianbiao ZhouChien-Shing Chen
Nov 22, 2011·PLoS Computational Biology·Joshua LequieuJeffrey D Varner
Nov 1, 2011·PloS One·Shujie YangKimberly K Leslie
Jul 19, 2012·PloS One·Eva Maria PutzEva Zebedin-Brandl
Oct 17, 2012·PloS One·Kennen B MacKaySteven G Clarke
Mar 17, 2011·The Oncologist·Leonel F Hernandez-Aya, Ana M Gonzalez-Angulo
Aug 31, 2010·Future Oncology·Sílvia Carvalho, Fernando Schmitt
Oct 14, 2011·Future Oncology·Qian ZhouWinnie Yeo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Cancer Epigenetics and Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Cancer Cell
David A Guertin, David M Sabatini
Nature Reviews. Cancer
Igor Vivanco, Charles L Sawyers
© 2022 Meta ULC. All rights reserved